The dual roles of PARP in DNA damage response and sustaining AR function taken in conjunction with data showing that abrogating AR signalling induces an “HRR-deficient” phenotype provide the basis for co-targeting AR and PARP concurrently to slow down tumour proliferation and disease progression [24]. The gene discussed is AR; the disease is neoplasm.